Vertex VX21-522-001

I'm Interested!

A Phase 1/2 Dose-escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Sex at Birth: Any
Age: Adult (18 - 64)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I/II
Conditions Being Studied: Lung, Cystic Fibrosis (CF)

Study Purpose

CF is caused by mutations in the genetic message that produce the CFTR protein. This is a study to evaluate the safety, tolerability, and efficacy of VX-522 treatment. VX-522 is designed to deliver a message that will provide cells with instructions to make normal CFTR protein.

Who Can Participate

Age: 18-65

Principal Investigator
Kimberly McBennett MD PhD

Department/Division
Pulmonology (Pediatrics)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: SITE00001783
StudyID: 2022-01008
ClinicalTrials.gov: NCT05668741

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422